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A B S T R A C T
Missing data are a prevailing problem in any type of data analyses. A participant variable is
considered missing if the value of the variable (outcome or covariate) for the participant is not
observed. In this article, various issues in analyzing studies with missing data are discussed.
Particularly, we focus on missing response and/or covariate data for studies with discrete,
continuous, or time-to-event end points in which generalized linear models, models for longitudinal
data such as generalized linear mixed effects models, or Cox regression models are used. We
discuss various classifications of missing data that may arise in a study and demonstrate in several
situations that the commonly used method of throwing out all participants with any missing data
may lead to incorrect results and conclusions. The methods described are applied to data from an
Eastern Cooperative Oncology Group phase II clinical trial of liver cancer and a phase III clinical trial
of advanced non–small-cell lung cancer. Although the main area of application discussed here is
cancer, the issues and methods we discuss apply to any type of study.
J Clin Oncol 30:3297-3303. © 2012 by American Society of Clinical Oncology
INTRODUCTION
In clinical trials, common end points include re-
sponse rate, immune response, quality of life (QOL),
and survival time. Investigators often wish to quan-
tify the effects of prognostic factors (covariates) on
the outcome to adjust for imbalances in covariates
that may persist after randomization or to model the
natural history of the disease. Longitudinally mod-
eling a patient self-reported outcome, such as QOL,
is also often of interest. Unfortunately, missing out-
come and/or covariate data are a common occur-
rence for most medical studies. Generally speaking,
a participant variable can be regarded as missing if
the value of the variable (outcome or covariate) for
the participant is not observed. Missing data frac-
tions may be large for some studies, especially for
studies in which the covariate consists of a labora-
tory measurement or biomarker that is difficult to
measure or for longitudinal studies in which there is
heavy study dropout because of treatment toxic-
ity.1,2 The omission of participants with missing
values can have a big impact on the analysis.3-5 Mea-
surements that require confidential, invasive, or
painful collection procedures, complicated labora-
tory analysis, and/or time-consuming coding or
compilation are more likely to be missing. The miss-
ing data can be in the form of missing outcome data,
such as missing QOL measurements in longitudinal
studies; missing response data in phase II cancer
clinical trials, such as missing tumor recurrence
times when a patient is never examined for tumor
recurrence; missing tumor characteristics, such as
tumor size, stage, grade, or location; or missing tox-
icity data. It is also quite common to have missing
data on prognostic variables, such as missing estro-
gen receptor status, nodal status, or size of tumor in
cancer studies; CD4 counts in AIDS studies; bio-
marker variables, such as -fetoprotein in liver can-
cer studies; phenotype or genotype information in
geneticstudies;bloodsamplemeasurements(hemo-
globin, cholesterol, and so on) in laboratory studies;
and so forth. It is important to distinguish between
the impact of missing outcome data and that of
missing covariate data in an analysis, because their
effects can be different depending on the goal of the
study. In this article, we characterize such differences
in Classifications of Missing Data, once we intro-
duce the various classifications of missing data.
In most analyses appearing in the medical liter-
ature, the most common way of dealing with miss-
ing (covariate or response) data is to just omit those
participants who have any missing data. Such an
analysis is called a complete case (CC) analysis. Us-
ing a CC analysis has been quite popular, because it
is the default analysis for most standard statistical
software. For example, in carrying out a Cox regres-
sion analysis in a popular statistical package such as
SAS (SAS Institute, Cary, NC), STATA (STATA,
College Station, TX), or R (http://www.r-project.org),
any participant with at least one missing covariate
value is omitted from the analysis. It is not uncom-
mon in many of these analyses that 30% of the par-
ticipants have missing data. This same default
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analysis is carried out for missing response data. In many situations,
the CC analysis is not an appropriate way to proceed and may lead to
inappropriate conclusions, as we will demonstrate in three examples.3
In this article, we address the various issues in analyzing studies with
missing data. We discuss the various classifications of missing data
that may arise in a study and demonstrate in several situations that a
CC analysis may lead to incorrect results and conclusions as well as to
a loss of power in the assessment of treatment effects and prognostic
factors. We first discuss the various missing data classifications in the
next section.
CLASSIFICATIONS OF MISSING DATA
To carry out statistical inference in the presence of missing data,
assumptions are needed regarding the process that generated the miss-
ing data, which is called the missing data mechanism. Reasons for
missingness include lost data, patient case report forms are incorrectly
filled out, personnel error, patient refusal, patient too ill to come to the
clinic, study dropout, faulty measurement device, limitations of mea-
surement device, data not entered or updated, and so forth. Valid
statistical inference for a particular study requires knowing or estimat-
ing the mechanism that generated the missing data. In summary, there
are essentially three classifications for missing data mechanisms. These
are now listed formally as follows.
Missing Completely at Random
Data are said to be missing completely at random (MCAR) if the
failure to observe a value does not depend on any data, either observed
or missing. Simple examples of MCAR include lost data, accidental
omission of an answer on a questionnaire, accidental breaking of
laboratory instrument, and personnel error. In a logistic regression,
for example, suppose that the response is completely observed for all
participants, whereas some of the covariates are missing for some
participants. Then the missing covariate values are MCAR if the
chance (probability) of observing the missing covariate is independent
of the response as well as independent of the values of the covariates
that are fully observed or the covariates that would have been observed
(ie, the missing covariates). Under MCAR, the observed data are just a
random sample of all the data. A CC analysis may result in larger SEs in
the model parameter estimates (ie, loss of efficiency) in this setting, but
no bias in the model parameter estimates is introduced when the data
are MCAR. Bias is defined as the average difference between model
parameter estimates and their true values.
Missing at Random
Data are said to be missing at random (MAR) if, given the ob-
served data, the failure to observe a value does not depend on the data
that are unobserved. For example, in cancer clinical trials, information
on the size of a primary tumor is often missing, and the size of the
primary tumor may depend on the type of the primary tumor, which
is often fully observed. If the probability of primary tumor size being
missing only depends on the type of primary tumor, then the missing-
ness is considered to be MAR.6,7 For a more general example involving
missing covariates, suppose that the response is completely observed,
whereas some covariates may be missing for some participants. The
missing values of the covariates are MAR if, given the observed data,
the probability of observing the missing covariate is independent of
the values of the missing covariate that would have been observed, but
this probability is not necessarily independent of the response or the
fully observed covariates. MAR is a more realistic assumption than
MCAR, but in this case, adjustments must be made, because the
observed covariates are no longer a random sample. Clearly, if the
missing data are MCAR, then they are MAR. In most MAR scenarios,
a CC analysis will be both inefficient and biased. In data that are MAR,
if missingness depends only on the fully observed covariates and not
on the response, then a CC analysis will lead to unbiased estimates.
However, if the missingness depends on the response variable (and
not necessarily on the fully observed covariates), then a CC analysis
will result in biased parameter estimates.3 Missing data that are MAR
or MCAR, along with the assumption that the parameters of the
missing data mechanism are distinct from the parameters of the sam-
pling model (ie, the joint distribution of the covariates and the re-
sponse), are said to be ignorably missing. In these cases, the missing
data mechanism can be ignored in making inferences about the pa-
rameters of the sampling model.
Missing Not at Random
The missing data mechanism is said to be nonignorable, or miss-
ing not at random (MNAR), if the failure to observe a value depends
on the value that would have been observed or other missing values in
the data set. MNAR data are most common in longitudinal studies in
which missingness is the result of study dropout, toxicity, or illness.
For example, the likelihood of obtaining a coping score on a patient in
a QOL study often depends on the coping score that would have been
observed; patients who are too sick because of toxicity of treatment
may not come to the clinic to fill out the QOL questionnaire. Another
possibility is that the patient refuses therapy because of toxicity and/or
his/her physical condition. A CC analysis in the MNAR setting also
leads to biased and inefficient parameter estimates. Valid inferences
for MNAR generally require specifying the correct model for the
missing data mechanism, distributional assumptions for the response,
or both. The resulting parameter estimates and statistics for testing
hypotheses may be sensitive to these assumptions. Little et al3 provide
an excellent discussion and examples of the various classifications of
missing data.
It is worth mentioning that unfortunately, one cannot determine
whether missingness is MNAR or MAR solely based on the data at
hand. For this reason, there is a growing consensus among statisticians
studying missing data methods that a key component of an analysis is
to carry out sensitivity analyses by fitting different missing data mech-
anisms to examine how sensitive the results are to the assumptions of
whether missingness is MNAR.
STATISTICAL METHODS FOR MISSING DATA
The appropriate statistical method depends on the type of missing
data mechanism that governs the missingness. Guidelines on missing
data in confirmatory clinical trials are under development (http://
www.ema.europa.eu/). In this section, we discuss the four most com-
monly used methods for handling missing data and statistical issues
regarding missing outcomes versus covariates.
Maximum Likelihood
A large class of model-based procedures arises from defining a
model for the variables with missing values and making statistical
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inferences based on what are called maximum likelihood (ML) meth-
ods. Model-based methods are quite flexible and clearly set forth
underlying model assumptions so that they can be evaluated. In
addition, SEs can be easily obtained based on the model using
appropriate algorithms and techniques,8 which take into account
the missing data. The literature on ML methods for missing data is
enormous, and the articles are too numerous to list here. For
example, the literature on missing covariates alone is
considerable.9-18 We refer the reader to the review article by Ibra-
him et al19 and the many references therein. For longitudinal data,
we refer the reader to the review article by Ibrahim et al20 and the
many references therein. For survival analysis, we refer the reader
to the articles by Chen et al21 and Herring et al.22 Modeling issues
and sensitivity analyses are addressed in several articles.2,14,15,23-25
Multiple Imputation
Multiple imputation (MI) has emerged as a popular technique
for dealing with missing data problems. The technique of multiple
imputation involves creating multiple complete data sets by filling in
values for the missing data. Then, each filled-in data set is analyzed as
if it were a complete data set.3,26 The inferences for the filled-in data
sets are then combined into one result by averaging over the filled-in
data sets. Many articles3,26-28 have described MI and some of its vari-
ants for missing covariates. It is important to mention here that the
imputed values are random; therefore, this randomness must be cap-
tured in the SEs of the parameter estimates. The basic idea behind MI,
along with parameter estimation and SEs, is described in the Appendix
(online only).
There are two types of MI techniques, which are called improper
and proper imputation.29 Improper imputation uses an imputation
model that is different from the analysis model, whereas in proper
imputation, the imputation model is based on the analysis model. For
example, for improper MI, the imputation may be carried out using a
normal linear model, and the analysis of the filled-in data may proceed
by a logistic regression.3 Improper MI yields biased estimators. Proper
MI, although computationally more intensive, yields unbiased esti-
mates with good large sample properties.3,26 Finally, we mention that
the motivation and basis of proper MI is Bayesian, but the idea of MI
itself is quite general and can be applied to other methods, such as hot
deck imputation.3
Fully Bayesian
Fully Bayesian (FB) methods for missing data (covariate and/or
response data) involve specifying distributions for all of the parame-
ters (called prior distributions) as well as specifying distributions for
the missing data. The missing data are then imputed from these
distributions.19,30-32 Bayesian methods can easily accommodate miss-
ing data without requiring new techniques for statistical inference. In
this sense, FB methods are perhaps the most powerful and most
general methods for dealing with missing data. ML and MI both have
Bayesian connections. The close connections between the ML, MI,
and FB procedures and details of the FB methodology are discussed in
more detail in the article by Ibrahim et al.19
Weighted Estimating Equations
A variety of other approaches requiring fewer model assump-
tions have been developed to account for missing observations. A
general approach called weighted estimating equations (WEEs) has
been proposed by Robins et al.33 WEE methods are the missing data
counterparts of what are called generalized estimating equations
(GEEs; ie, WEEs are GEE methods adapted to the presence of missing
data). General weighted estimating equations34 are often called doubly
robust in the sense that to obtain an unbiased estimate of the regres-
sion parameters, either the missing data mechanism or the estimating
equations for the missing data given the observed data must be cor-
rectly specified, but not both. WEE methods for missing covariates
have been discussed in many articles.16,35-40 We mention here that
GEEs are indeed a valid procedure when the missing data are MCAR,
but they are generally biased if missingness is MAR or MNAR.
Once a formal statistical model is formulated, estimation can be
performed, for example, using any of the four formal methods men-
tioned, which is a far superior way to handle missing data compared
with the ad-hoc CC method. These formal methods, however, can be
computationally intensive and may not be available in standard statis-
tical packages, such as SAS, STATA, S-Plus (version 3.3; Statistical
Sciences, Seattle, WA), or R. The ML method is often viewed as the
gold standard in model fitting. ML methods for generalized linear
models are available in some statistical packages, and various versions
of MI are available in SAS as well as other packages. FB methods are
available in both SAS and WinBUGS (Medical Research Council Bio-
statistics Unit, Cambridge, United Kingdom); MI, FB, and ML meth-
ods often produce similar results in many settings. More details about
the software are provided in Software section.
Missing Outcomes Versus Covariates
The impact of missing covariates versus that of missing outcomes
on the estimates in a regression model may be quite different. First, we
mention that if the data set only has missing responses, and the miss-
ing responses are assumed to be MAR, then a CC analysis will lead to
unbiased estimates of the regression coefficients (ie, a CC analysis and
an ML analysis are equivalent in this case). However, when the re-
sponses are MNAR, then the CC analysis as well as the ML analysis
assuming MAR will lead to biased estimates. With missing covariates,
the story is different. When we have only missing covariates in a
regression analysis (no missing responses), then the ML analyses ei-
ther assuming MAR or MNAR are superior to the CC analysis in terms
of bias and efficiency of the parameter estimates. When we have both
missing responses and covariates in a data set, as is common in longi-
tudinal studies, then an ML analysis either assuming MAR or MNAR
is superior to the CC analysis in terms of bias and efficiency as long as
the sampling model and the missing data mechanism are assumed to
be correct or approximately correct. If the sampling model and/or the
missing data are badly misspecified in an ML analysis, then the ML
method can yield poor results. We also refer the reader to the review
articles by Ibrahim et al19,20 for extensive discussions and references on
missing data in generalized linear models and models for longitudinal
data. We mention here that in analyzing time-to-event data in a
randomized clinical trial, one typically examines the treatment
effect without adjusting for covariates. This is valid in cases where
the censoring mechanism for the time to event only depends on the
treatment group and does not depend on other covariates. When
the censoring mechanism depends on other covariates, such as age,
sex, and so on, then the assessment of the treatment effect should
account for these covariates via a Cox regression in time-to-event
studies, for example. There are other simple adjustments in some
specific scenarios (eg, using propensity score methods for adjusting
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for covariates in the assessment of treatment effects41,42 and the
missing data indicator [MDI] method to adjust for partially miss-
ing baseline measurements43).
SOFTWARE
Existing commercial software for dealing with missing data is still
quite limited, although there have been significant advances in soft-
ware in the past 3 years. The recent article by Horton et al44 provides an
excellent detailed summary of existing software for missing data. The
SAS package has the PROC MI procedure for implementing the mul-
tiple imputation technique for missing data. However, the PROC MI
procedure is best suited for normally distributed data and may not
work well with right-censored survival data, discrete responses, or
covariate data that are not continuous and normally distributed. Thus,
the PROC MI procedure may not be well suited for carrying out Cox
regression with missing covariate data or a longitudinal analysis with
missing discrete outcomes and/or covariates, for example. Other sta-
tistical packages that carry out MI using a variety of techniques include
S-Plus, SOLAS (Statistical Solutions, Saugus, MA), Amelia II (http://
gking.harvard.edu/amelia), Hmisc (http://www.inside-r.org/packages/
cran/Hmisc), ICE (within STATA), IVEware (http://www.isr.umich
.edu/src/smp/ive), and MICE (http://mice-software.com). All of these
packages have been discussed in detail; we refer the reader to the article
by Horton et al44 for an excellent discussion. The S-Plus package
software developed by Schafer45 uses the ML method for missing
response data for categorical or normally distributed responses. S-Plus
is also quite limited as far as fitting models with missing data in Cox
regression, longitudinal data, and covariate data are concerned. The
STATA package has some built-in ad-hoc imputation techniques for
handling missing covariate data for normally distributed response
data. More recently, the software package XMISS in the LogXact
module (Cytel, Cambridge, MA) carries out the ML method for MAR
categorical covariates in generalized linear models.12 In the setting
with MAR categorical covariates, PROC MI and XMISS may yield
different results. WinBUGS46 is also quite powerful for implementing
the FB method in missing data settings. WinBUGS can essentially
handle any type of missing data problem, including missing MAR or
MNAR covariates and/or responses in the Cox model, models for
longitudinal data, or generalized linear models. When using appropri-
ate prior distributions, WinBUGS yields results similar to those of ML
and MI.
MISSING DATA IN COX REGRESSION AND LONGITUDINAL
STUDIES
In this section, we present some examples illustrating the importance
of incorporating participants with missing data in an analysis. We will
compare inferences based on CC analyses with those of the ML
method for three common settings in clinical trials: phase II time-to-
event clinical trial with MAR covariate (biomarker) data; phase III
time-to-event clinical trial with MAR (or MNAR) baseline covariate
data; and phase III clinical trial with MAR or MNAR longitudinal
response (QOL) data (Appendix; Appendix Tables A1 and A2, online
only). In each example, we will show how misleading conclusions can
be obtained when a CC analysis is carried out.
Example 1: Liver Cancer Data
We consider a liver cancer data set including 190 patients from
two Eastern Cooperative Oncology Group clinical trials to evaluate
new treatments in patients with primary liver cancer.47,48 We are
primarily interested in how survival time from study entry to death
differs with respect to three baseline characteristics. These three base-
line characteristics are associated jaundice (yes or no) and two bio-
chemical markers -fetoprotein and -globulin, each classified as
normal or abnormal. Patients with abnormal biochemical markers
and/or jaundice are all expected to have shorter survival. Jaundice is
always observed, but of the 190 patients in the data set, 109 (57%) are
Table 1. Parameter Estimates and P Values for Liver Cancer Data
Effect Estimate SE P
-fetoprotein
CC 0.221 0.234 .344
MDI 0.255 0.150 .090
ML 0.392 0.155 .012
-globulin
CC 0.516 0.233 .027
MDI 0.538 0.195 .006
ML 0.536 0.154 .001
Jaundice
CC 0.092 0.256 .720
MDI 0.243 0.155 .116
ML 0.162 0.155 .295
Abbreviations: CC, complete case; MDI, missing data indicator; ML, maxi-
mum likelihood.
























Both covariates missing 27
One covariate missing 92
Abbreviations: FACT-G, Functional Assessment of Cancer Therapy–General;
QOL, quality of life; SD, standard deviation.
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missing -fetoprotein and/or -globulin, of whom 15 (8%) are miss-
ing -fetoprotein, 102 (54%) are missing -globulin, and eight (4%)
are missing both. The biochemical markers, which are not always easy
to obtain, are the covariates with missing values. In the univariate
analysis, the estimate, SE, and P value for jaundice are 0.218, 0.153,
and 0.152, respectively. However, jaundice is highly significant in
predicting the missingness of -globulin in a multiple logistic regres-
sion model for the missing indicator. The adjusted odds ratio, 95% CI,
and P value of observing -globulin are 3.213, 1.723 to 5.989, and
 .001 for jaundice, respectively. Because the missing data indicator
does depend on jaundice, the assumption of MCAR does not hold for
the data. With 57% missing data, a CC analysis using the 81 partici-
pants with no missing data could produce highly biased or inefficient
estimates, because MAR seems tenable, but MCAR does not, for these
data. Table 1 lists the estimates of the parameters for the Cox regres-
sion model using the CC, MDI, and ML methods (ML method as-
sumes MAR). The ML method yields different conclusions than the
CC, whereas the MDI method is much more consistent with the ML
than the CC method. In fact, in terms of P values and estimates, the
MDI method produces results similar to those of the ML method and
yields conclusions similar to those of the ML method. Regarding the
effects of the two biochemical markers, -globulin is significant ( 
0.05) using all three methods (ML, MDI, CC), but -fetoprotein is
significant (  0.05) under the ML method, marginally not signifi-
cant under MDI, and not significant under the CC method. Also, the
SE seems to be greatly reduced with the ML and MDI methods in
general as compared with the CC method. For example, the estimated
effect of -globulin is approximately the same using the CC and ML
methods, but the estimated SE is reduced from 0.233 for CC to 0.155
for the ML method, which is a 34% reduction. The MDI estimate
corresponding to the unknown category of -fetoprotein is 0.959, and
the MDI estimate corresponding to the unknown category of
-globulin is 0.01. These results explain why the ML estimate of
-fetoprotein is larger than the MDI estimate, and the ML and MDI
estimates are similar for -globulin, because the MDI method treats
the unknown category as the reference group in this example. For this
example, the ML and MDI methods produce similar conclusions. To
examine the MAR assumption under ML, we carried out several
sensitivity analyses by fitting several MNAR models and found that the
estimates and P values under these MNAR models were similar to the
estimates under the MAR model. In addition, the P values corre-
sponding to the two missing covariates in the logistic regression mod-
els for the missing indicators are greater than .14, suggesting that there
is no statistically significant evidence against the MAR assumption for
these data. For additional details on the modeling and analyses of these
data, we refer to reader to the work of Lipsitz et al14 and Lipsitz and
Ibrahim.1
Example 2: Phase III Advanced Non–Small-Cell Lung
Cancer Clinical Trial
We consider data from a phase III clinical trial of advanced
non–small-cell lung cancer conducted by the University of North
Carolina at Chapel Hill (LCCC 9719). The results of this study were
reported by Socinski et al.49 The goal of this trial was to compare a
Table 3. Parameter Estimates and P Values for Small-Cell Lung
Cancer Data
Effect
Full Model Reduced Model
Estimate SE P Estimate SE P
Treatment
CC 0.471 0.253 .062 0.383 0.193 .047
MDI 0.469 0.174 .007 0.486 0.168 .004
MAR 0.477 0.175 .006 0.491 0.169 .004
MNAR 0.478 0.175 .006 0.491 0.169 .004
Sex
CC 0.068 0.243 .780
MDI 0.177 0.178 .320
MAR 0.174 0.180 .334
MNAR 0.174 0.180 .336
Age
CC 0.020 0.130 .878
MDI 0.023 0.088 .795
MAR 0.021 0.090 .812
MNAR 0.021 0.090 .814
Apex
CC 0.879 0.411 .032 0.804 0.371 .030
MDI 0.862 0.372 .021 0.777 0.366 .034
MAR 0.914 0.381 .016 0.810 0.374 .030
MNAR 0.923 0.380 .015 0.808 0.372 .030
QOL FACT-G score
CC 0.138 0.119 .247
MDI 0.065 0.100 .518
MAR 0.052 0.105 .624
MNAR 0.051 0.106 .628
NOTE. If we fit treatment alone to the data with 230 observations, the
estimate, SE, and P value are 0.482, 0.168, and .004, respectively; if we fit
treatment adjusting for sex, the estimate, SE, and P value for treatment are
0.477, 0.168, and .005, respectively; if we fit treatment adjusting for sex and
age, the estimate, SE, and P value for treatment are 0.465, 0.174, and .008,
respectively; and if we fit treatment adjusting for sex, age, and apex, the
estimates, SEs, and P values for treatment are 0.472, 0.175, and .007 under
MAR and 0.473, 0.175, and .007 under MNAR, respectively. In addition, we
add the QOL FACT-G score to the reduced model in the table. Under this
three-covariate model, the estimates, SEs, and P values for treatment are
0.486, 0.234, and .038 under CC, 0.484, 0.168, and .004 under MDI, and
0.489, 0.169, and .004 under MAR and MNAR, respectively; the estimates,
SEs, and P values for apex are 0.863, 0.407, and .034 under CC, 0.819, 0.369,
and .027 under MDI, 0.853, 0.380, and .025 under MAR, and 0.863, 0.380, and
.023 under MNAR, respectively; and the estimates, SEs, and P values for QOL
FACT-G score are 0.146, 0.115, and .204 under CC, 0.084, 0.096, and .381
under MDI, 0.062, 0.100, and .531 under MAR, and 0.061, and 0.100, and
.542 under MNAR, respectively.
Abbreviations: CC, complete case; FACT-G, Functional Assessment of
Cancer Therapy–General; MAR, missing at random; MDI, missing data indica-
tor; MNAR, missing not at random; QOL, quality of life.
Table 4. Minimal Information for Handling Missing Data
Option Minimal Information
1 Summary of missing covariate and/or response data, including
fractions of missing data
2 Summary of how missing values are analyzed, including: (1) CC
analysis as benchmark analysis; (2) logistic regression analysis
of missing indicators using completely observed variables as
covariates; (3) if relevant, summary of models and MAR analysis
results using either ML, MI, FB, or WEE methods; (4) if
relevant, summary of MNAR models and MNAR analysis using
either ML, MI, FB, or WEE methods; (5) if relevant, sensitivity
analysis results for MNAR; and (6) if relevant, comparison and
summary of results of CC, MDI, MAR, and MNAR
Abbreviations: CC, complete case; FB, fully Bayesian; MI, multiple imputa-
tion; ML, maximum likelihood; MAR, missing at random; MDI, missing data
indicator; MNAR, missing not at random; WEE, weighted estimating equation.
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defined duration of therapy (arm A) with continuous therapy fol-
lowed by second-line therapy (arm B) to determine optimal duration
of therapy in patients with non–small-cell lung cancer. LCCC 9719
included 230 patients. We consider here five prognostic factors: treat-
ment (two arms: A and B, coded as 1 and 0), sex (female and male,
coded as 0 and 1), age in years, apex (two levels: 0 and 1, where 1
indicates that the tumor was at the top of the lung), and baseline QOL
Functional Assessment of Cancer Therapy–General (FACT-G) score.
For these five prognostic factors, apex and QOL FACT-G score had
missing information, whereas treatment, sex, and age were completely
observed for all patients. In this data set, there is a total missing
covariate data fraction of 51.74% on these two covariates. The out-
come variable is time to progression in months, which is continuous
and subject to right censoring. The median follow-up time is 3.94
months (range, 0.10 to 27.61 months). A summary of the data set is
provided in Table 2.
We fit the Cox regression model to the LCCC 9719 data with
these five covariates. We carry out four analyses (ie, CC, MDI, MAR
covariates, and MNAR covariates). The missing data mechanism for
the model assuming MNAR is a logistic regression model with survival
time, missing data indicator, apex, treatment, sex, age, and QOL as
covariates in the model. There are no interaction terms in the missing
data mechanism. Table 3 lists ML estimates along with SEs and P
values for the five covariates. In the CC analysis, the P value for
treatment is .036 if we fit the treatment covariate alone; if we fit the
treatment covariate along with sex, age, apex, and QOL, the P value
for treatment is .062,whereas thePvalueforapex is .032. Intheunivariate
Cox regression analysis, sex and age are not significant, and the corre-
sponding P values are 0.332 and 0.433, respectively. However, sex is
significant in the logistic regression model for the missing indicator of
apex; the odds ratio and P value are 0.49 and .033, respectively. Also, an
older patient tends to have a worse QOL FACT-G score (P  0.006).
Thus, it is of clinical importance to include both of these covariates
in the analysis of these data. In the MDI analysis, the P value for
treatment is .007, whereas the P value for apex is .021. Also, the P
values are .006 and .006 for treatment and .016 and .015 for apex
under the MAR and MNAR models, respectively. We also consider
a reduced model with treatment and apex only. Under this reduced
model, the P values for treatment are .047, .004, .004, and .004
corresponding to CC, MDI, MAR, and MNAR, respectively,
whereas the P values for apex are .030, .034, .030, and .030 corre-
sponding to CC, MDI, MAR, and MNAR, respectively. These
results imply that under all three methods (MDI, MAR, MNAR),
treatment and apex are significantly associated with time to disease
progression at the 5% significance level. Thus, continuous therapy
followed by second-line therapy may have a strong effect (ie, more
beneficial) compared with defined duration of therapy with respect
to time to progression based on an analysis using all patients. Also,
the SEs based on the ML method (MAR or MNAR) are consistently
smaller than those from the CC analysis for all of the covariates.
In addition, from Table 3, we see that both sets of ML estimates of
the regression coefficients for all covariates are similar under the MAR
and MNAR scenarios. Because the MAR model is a special case (ie, a
submodel) of the MNAR model, these results suggest that there is no
evidence against the MAR assumption in the LCCC 9719 data. More-
over, we note that the MDI, MAR, and MNAR methods all yield
similar conclusions about the effects of the covariates. This example
shows the importance of using all of the participants whenever possi-
ble in carrying out an analysis. For more details on the modeling and
analysis of these data, we refer the reader to the article by Chen et al.50
CONCLUSION
We see from these examples how statistical analyses may be affected if
participants with missing values are omitted from an analysis. Mis-
leading results might be obtained regarding the effect of treatment,
unreliable P values may be obtained, and assessments of the impor-
tance of prognostic factors may be inaccurate. The MAR results for
examples 1 and 2 can be obtained using PROC MI in SAS or Win-
BUGS. The MNAR results can be obtained only using WinBUGS. In
addition, the MDI results are easily obtained in any statistical package
that carries out Cox regression; this method is much easier to imple-
ment than the ML method, because it does not require special tools or
new statistical methods for model fitting. Table 4 provides a list of the
minimal information that should be included in the methods section
of an article describing how missing data should be handled. In gen-
eral, it is strongly recommended that one avoid performing a CC
analysis whenever possible; one should use ML, MI, FB, or WEE
methods as appropriate. Finally, it is important to note here that the
ML (MAR or MNAR) and MDI methods may yield imprecise esti-
mates and P values, and hence wrong conclusions, if the missing data
fraction is too high in a given data set. As a general rule of thumb, if the
missing data fraction for a given variable (covariate or outcome) is
greater than 50%, then one may obtain imprecise estimates and P
values in the regression model. In such cases, one must conduct these
analyses with great caution and perform several sensitivity analyses.
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